PR PHARMACEUTICALS: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
PR PHARMACEUTICALS
Largest movements
- Receivables within one year +€490
up €490 (+2.6%), from €19,159 to €19,649
- Other debts +€12,120
up €12,120 (+4.1%), from €296,115 to €308,235
- Profit (loss) carried forward -€11,511
down €11,511 (-3.4%), from -€343,357 to -€354,867
- Taxes +€4,063
new in 2025: €4,063
- Financial charges -€611
down €611 (-7.4%), from €8,198 to €7,588
- Financial income +€490
new in 2025: €490
- Other operating charges -€442
down €442 (-78.7%), from €562 to €120
- Gross operating margin -€23
down €23 (-10.9%), from -€208 to -€230
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €19,162 | €19,680 | +€517 | +2.7% |
| Current assets | 29/58 | €19,162 | €19,680 | +€517 | +2.7% |
| Amounts receivable within one year | 40/41 | €19,159 | €19,649 | +€490 | +2.6% |
| Other amounts receivable | 41 | €19,159 | €19,649 | +€490 | +2.6% |
| Cash at bank and in hand | 54/58 | €3 | €31 | +€27 | +780% |
| Total equity and liabilities | 10/49 | €19,162 | €19,680 | +€517 | +2.7% |
| Equity | 10/15 | -€277,101 | -€288,612 | -€11,511 | -4.2% |
| Contributions | 10/11 | €66,256 | €66,256 | = | 0.0% |
| Capital | 10 | €66,256 | €66,256 | = | 0.0% |
| Issued capital | 100 | €70,000 | €70,000 | = | 0.0% |
| Uncalled capital | 101 | €3,744 | €3,744 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€343,357 | -€354,867 | -€11,511 | -3.4% |
| Amounts payable | 17/49 | €296,264 | €308,292 | +€12,028 | +4.1% |
| Amounts payable within one year | 42/48 | €296,264 | €308,292 | +€12,028 | +4.1% |
| Financial debts | 43 | €1 | - | -€1 | |
| Credit institutions | 430/8 | €1 | - | -€1 | |
| Trade debts | 44 | €148 | €57 | -€91 | -61.4% |
| Suppliers | 440/4 | €148 | €57 | -€91 | -61.4% |
| Other amounts payable | 47/48 | €296,115 | €308,235 | +€12,120 | +4.1% |
| Other operating charges | 640/8 | €562 | €120 | -€442 | -78.7% |
| Gross operating margin | 9900 | -€208 | -€230 | -€23 | -10.9% |
| Operating profit (loss) | 9901 | -€770 | -€350 | +€420 | +54.5% |
| Financial income | 75/76B | - | €490 | +€490 | |
| Recurring financial income | 75 | - | €490 | +€490 | |
| Financial charges | 65/66B | €8,198 | €7,588 | -€611 | -7.4% |
| Recurring financial charges | 65 | €8,198 | €7,588 | -€611 | -7.4% |
| Profit (loss) for the period before taxes | 9903 | -€8,969 | -€7,448 | +€1,521 | +17.0% |
| Income taxes | 67/77 | - | €4,063 | +€4,063 | |
| Profit (loss) for the period | 9904 | -€8,969 | -€11,511 | -€2,542 | -28.3% |
| Profit (loss) for the period to be appropriated | 9905 | -€8,969 | -€11,511 | -€2,542 | -28.3% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 13 October 2026 via checked.be.